Protein optimization, resistance training, and behavioral changes help maintain results long-term
Briefly, FFAs can reduce the tyrosine phosphorylation of insulin receptor substrate-1 by activating the serine/threonine kinase, thereby aggravating IR (151)
Yes, early intervention with medications like phentermine is safe when properly monitored
In 2022, total Medicare expenditures on the GLP-1/GIP agonists were $5.7 billion
Early-phase human trials describe significant weight-related endpoint changes, alterations in energy expenditure markers, and modulation of glucose homeostasis indicators
How the Framework Fits Together The hormone-aware metabolic framework places GLP-1 microdosing within a broader system of metabolic care rather than treating it as a stand-alone solution